title: [Rheumatologic manifestations of Lyme borreliosis].
abstract: OBJECTIVE
  Lyme borreliosis is a multisystemic infection caused by the spirochaete Borrelia burgdorferi. In European endemic areas like northeast France, articular manifestations are, after neuroborreliosis, the most frequent extra-cutaneous features observed. Among the pathogenic species of Borrelia, Borrelia burgdorferi sensu stricto is the most frequently identified during Lyme arthritis, but others species also seem to be involved.
  
  
  BACKGROUND
  The diagnosis of Lyme arthritis is usually based on combined clinical data and serological laboratory tests. In atypical forms, detection of bacterial DNA could be useful. While mechanisms involved in acute Lyme arthritis are beginning to be better understood, the pathogenesis of chronic arthritis, which concerns about 10% of the patients, remains unknown. Two hypotheses are proposed to explain the prolonged evolution of the articular disease: a chronic persistence of Borrelia burgdorferi, which evades the host immune system within the joint and/or an autoimmune mechanism by molecular mimicry. The antibiotic therapy is codified in acute arthritis, but is not really adapted in chronic Lyme arthritis or post-Lyme syndrome.
  
  
  CONCLUSIONS
  To prevent the disease, the vaccine available in the United States does not offer complete protection and is not useful in Europe since the species heterogeneity is important for the outer surface protein A. A better understanding of Lyme disease pathogenesis can subsequently lead to new therapeutic or preventive approaches.
authors: Service de rhumatologie, hôpital de Hautepierre, CHU, 1, avenue Molière, 67098 Strasbourg, France. jean.sibilia@wanadoo.fr
authors: J
authors: J
authors: Sibilia
authors: B
authors: B
authors: Jaulhac
authors: F X
authors: FX
authors: Limbach
mesh_terms: D000208:Acute Disease; D025065:Borrelia burgdorferi / Q000235:genetics / Q000472:pathogenicity*; D005060:Europe; D006801:Humans; D015994:Incidence; D008193:Lyme Disease / Q000150:complications* / Q000276:immunology*; D022123:Lyme Disease Vaccines / Q000276:immunology; D011379:Prognosis; D012216:Rheumatic Diseases / Q000209:etiology* / Q000382:microbiology* / Q000503:physiopathology; D012703:Serotyping; D014481:United States
chemical_list: D022123:Lyme Disease Vaccines